Table 1 Baseline characteristics

Age, years

46 (27–61)

47 (35–59)

0.4

FIGO stage

0.046

 IB1

24 (35.3)

28 (45.9)

 IB2

5 (7.4)

12 (19.7)

 IIA1

32 (47.1)

17 (27.9)

 IIA2

7 (10.3)

4 (6.6)

Tumor size

0.097

 >4.0cm

11 (16.2)

14 (23)

 >2cm, ≤4cm

44 (64.7)

28 (45.9)

 ≤2.0cm

13 (19.1)

19 (31.1)

Histology

0.510

 Squamous cell carcinoma

62 (91.2)

58 (95.1)

 Adenocarcinoma

4 (5.9)

1 (1.6)

 Others

2 (2.9)

2 (3.3)

Tumor differentiation

0.09

 1

3 (4.4)

2 (3.3)

 2

45 (66.2)

32 (52.5)

 3

20 (29.4)

27 (44.3)

Pelvic lymph node

0.053

 Positive

20 (29.4)

28 (45.9)

 Negative

48 (70.6)

33 (54.1)

LVSI

0.004

 Positive

13 (19.1)

26 (42.6)

 Negative

55 (80.9)

35 (57.4)

Stromal invasion

0.753

 Invasion depth>1/2

58 (85.3)

47 (77.0)

 Invasion depth<1/2

10 (14.7)

12 (19.7)

 No

0 (0)

2 (3.3)

Surgical margin

0.212

 Positive

5 (7.4)

1 (1.6)

 Negative

63 (92.6)

60 (98.4)

Prognostic risk group

0.053

 High-risk

21 (30.9)

29 (47.5)

 Intermediate-risk

47 (69.1)

32 (52.5)